Jeff Jones, Cullinan Oncology CMO
June 3, 2022 05:12 PM EDT
R&D

#AS­CO22: With me­di­an dura­bil­i­ty da­ta, Cul­li­nan aims to 'dis­tin­guish it­self' from Takeda's Exkiv­i­ty and J&J's Ry­bre­vant in ex­on 20 NSCLC

Kyle LaHucik

Senior Reporter

CHICA­GO — In its “first time on a big­ger stage” at this week­end’s AS­CO con­fer­ence, Cul­li­nan On­col­o­gy thinks it has the da­ta to “dis­tin­guish it­self” …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times